EU/3/07/494: Orphan designation for the treatment of chronic lymphocytic leukaemia

lenalidomide

Table of contents

Overview

On 19 November 2007, orphan designation (EU/3/07/494) was granted by the European Commission to Celgene Europe Limited, UK, for lenalidomide for the treatment of chronic lymphocytic leukaemia.

The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in July 2018.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2019 on request of the Sponsor.

Key facts

Active substance
lenalidomide
Intended use
Treatment of chronic lymphocytic leukaemia
Orphan designation status
Withdrawn
EU designation number
EU/3/07/494
Date of designation
19/11/2007
Sponsor
Celgene Europe B.V.
Winthontlaan 6 N
3526 KV Utrecht
Tel. +31 (0)30 284 4547
E-mail: medinfo.intl@celgene.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating